The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

The authors report the results of the phase II PEMDAC clinical study testing the combination of the HDAC inhibitor entinostat with the anti- PD-1 antibody pembrolizumab in uveal melanoma. Low tumor burden, a wildtype BAP1 gene in the tumor or iris melanoma correlates with response and longer surviva...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lars Ny, Henrik Jespersen, Joakim Karlsson, Samuel Alsén, Stefan Filges, Charlotta All-Eriksson, Bengt Andersson, Ana Carneiro, Hildur Helgadottir, Max Levin, Ingrid Ljuslinder, Roger Olofsson Bagge, Vasu R. Sah, Ulrika Stierner, Anders Ståhlberg, Gustav Ullenhag, Lisa M. Nilsson, Jonas A. Nilsson
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/81ef06cf1a674812b72c3509644a228b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:81ef06cf1a674812b72c3509644a228b
record_format dspace
spelling oai:doaj.org-article:81ef06cf1a674812b72c3509644a228b2021-12-02T15:09:17ZThe PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma10.1038/s41467-021-25332-w2041-1723https://doaj.org/article/81ef06cf1a674812b72c3509644a228b2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25332-whttps://doaj.org/toc/2041-1723The authors report the results of the phase II PEMDAC clinical study testing the combination of the HDAC inhibitor entinostat with the anti- PD-1 antibody pembrolizumab in uveal melanoma. Low tumor burden, a wildtype BAP1 gene in the tumor or iris melanoma correlates with response and longer survival.Lars NyHenrik JespersenJoakim KarlssonSamuel AlsénStefan FilgesCharlotta All-ErikssonBengt AnderssonAna CarneiroHildur HelgadottirMax LevinIngrid LjuslinderRoger Olofsson BaggeVasu R. SahUlrika StiernerAnders StåhlbergGustav UllenhagLisa M. NilssonJonas A. NilssonNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Lars Ny
Henrik Jespersen
Joakim Karlsson
Samuel Alsén
Stefan Filges
Charlotta All-Eriksson
Bengt Andersson
Ana Carneiro
Hildur Helgadottir
Max Levin
Ingrid Ljuslinder
Roger Olofsson Bagge
Vasu R. Sah
Ulrika Stierner
Anders Ståhlberg
Gustav Ullenhag
Lisa M. Nilsson
Jonas A. Nilsson
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
description The authors report the results of the phase II PEMDAC clinical study testing the combination of the HDAC inhibitor entinostat with the anti- PD-1 antibody pembrolizumab in uveal melanoma. Low tumor burden, a wildtype BAP1 gene in the tumor or iris melanoma correlates with response and longer survival.
format article
author Lars Ny
Henrik Jespersen
Joakim Karlsson
Samuel Alsén
Stefan Filges
Charlotta All-Eriksson
Bengt Andersson
Ana Carneiro
Hildur Helgadottir
Max Levin
Ingrid Ljuslinder
Roger Olofsson Bagge
Vasu R. Sah
Ulrika Stierner
Anders Ståhlberg
Gustav Ullenhag
Lisa M. Nilsson
Jonas A. Nilsson
author_facet Lars Ny
Henrik Jespersen
Joakim Karlsson
Samuel Alsén
Stefan Filges
Charlotta All-Eriksson
Bengt Andersson
Ana Carneiro
Hildur Helgadottir
Max Levin
Ingrid Ljuslinder
Roger Olofsson Bagge
Vasu R. Sah
Ulrika Stierner
Anders Ståhlberg
Gustav Ullenhag
Lisa M. Nilsson
Jonas A. Nilsson
author_sort Lars Ny
title The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
title_short The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
title_full The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
title_fullStr The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
title_full_unstemmed The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
title_sort pemdac phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/81ef06cf1a674812b72c3509644a228b
work_keys_str_mv AT larsny thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT henrikjespersen thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT joakimkarlsson thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT samuelalsen thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT stefanfilges thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT charlottaalleriksson thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT bengtandersson thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT anacarneiro thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT hildurhelgadottir thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT maxlevin thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT ingridljuslinder thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT rogerolofssonbagge thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT vasursah thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT ulrikastierner thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT andersstahlberg thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT gustavullenhag thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT lisamnilsson thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT jonasanilsson thepemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT larsny pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT henrikjespersen pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT joakimkarlsson pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT samuelalsen pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT stefanfilges pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT charlottaalleriksson pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT bengtandersson pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT anacarneiro pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT hildurhelgadottir pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT maxlevin pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT ingridljuslinder pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT rogerolofssonbagge pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT vasursah pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT ulrikastierner pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT andersstahlberg pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT gustavullenhag pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT lisamnilsson pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
AT jonasanilsson pemdacphase2studyofpembrolizumabandentinostatinpatientswithmetastaticuvealmelanoma
_version_ 1718387824141533184

Ejemplares similares